This department is offering a grant to support the development and validation of innovative technologies aimed at improving the quality of biospecimens used in cancer research and clinical care. The grant seeks to address pre-analytical degradation issues in cancer-relevant biospecimens by developing tools, instrumentation, and methods to preserve sample integrity and establish quality control criteria. The goal is to enhance research in cancer biology, early detection, clinical diagnosis, treatment, and epidemiology, while reducing pre-analytical variations that affect sample quality. This grant opportunity is part of the NCI’s Innovative Molecular Analysis Technologies (IMAT) Program.
Opportunity ID: 311793
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-19-022 |
| Funding Opportunity Title: | Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 07, 2019 |
| Last Updated Date: | Jan 07, 2019 |
| Original Closing Date for Applications: | Sep 27, 2019 |
| Current Closing Date for Applications: | Sep 27, 2019 |
| Archive Date: | Nov 02, 2019 |
| Estimated Total Program Funding: | $900,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses State governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Private institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts City or township governments Special district governments Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-022.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | FORMS-E | PKG00247358 | Feb 07, 2019 | Sep 27, 2019 | View |
Package 1
Mandatory forms
311793 RR_SF424_2_0-2.0.pdf
311793 PHS398_CoverPageSupplement_4_0-4.0.pdf
311793 RR_OtherProjectInfo_1_4-1.4.pdf
311793 PerformanceSite_2_0-2.0.pdf
311793 RR_KeyPersonExpanded_2_0-2.0.pdf
311793 RR_Budget_1_4-1.4.pdf
311793 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
311793 RR_SubawardBudget30_1_4-1.4.pdf
311793 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
